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Wang et al. have provided new and novel evidence about 
the importance of using α-fetoprotein (ALP) and glypican-3 
(GPC-3) mRNA detection in peripheral blood of the patients 
with hepatocellular carcinoma (HCC) recurrence after or-
tothopic liver transplantation (OLT) (1). HCC keeps on as ma-
jor universal health apprehension ensuing in more than 1 
million caner associated deaths annually (2, 3). These results 
are frankly attributable to a commonly pitiable prognosis 
for patients with HCC, with few attaining 5-year survival (3). 
Although the incidence of HCC in North America has been 
comparatively low, a stable augmentation has taken place 
since the 1980s, while the prevalence of most other cancers 
has turned down (4). Because of the comparative resistance 
of HCC to systemic chemotherapy, pioneering treatments 
such as transarterial chemoembolization and yttrium 90–
labeled radiotherapy has been extended to improve disease 
manage. 
HCC often happens in the setting of cirrhosis, total hepa-
tectomy with OLT affords one of the only prospective cures 
for  both  diseases  so  at  present  liver  transplantation  has 
been established as a cure of patients with HCC and associ-
ated cirrhosis. In spite of this, the return of HCC after liver 
transplantation  remains  an  unanswered  concern.  Mazza-
ferro et al. proved that a stringent assortment of HCC pa-
tients, focusing on tumor-staging before transplantation, 
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could facilitate an acceptable tumor-free survival. They also 
found poor outcome among patients whose tumors did not 
descend within the criteria (i.e., the “Milano criteria”) (5). 
In  general,  immunosuppressed  organ  allograft  recipients 
are at increased jeopardy of developing a number of ma-
lignancies. Vivarelli et al. (6) confirmed that the amount of 
immunosuppressant  agents  (cyclosporine)  administered 
was associated with HCC recurrence after liver transplanta-
tion. Recent studies showed that the risk of HCC recurrence 
subsequent  liver  transplantation  is  larger  with  antibody 
treatment than with other classes of immunosuppressive 
agents (7). Several researches have been performed to find 
a reliable tumor marker for HCC and HCC recurrence after 
OLT. During the past 50 years, AFP has been used as a serum 
tumor marker for HCC, but its function as a probable predic-
tive factor in OLT for HCC has not been established. AFP is a 
major transport protein in the fetus (8) and being secreted 
in only about 70% of HCC cases, so both false-negative and 
false-positive rates are elevated when considering AFP as the 
serological marker for the detection of HCC (9). In general, 
patients have an initially high serum AFP level when HCC is 
diagnosed. Serum AFP level is also considered an effective 
tumor marker in the surveillance of HCC recurrence (10). It 
is expected that recurrent HCC to have the identical bioac-
tivity as the primary tumor and to exude high levels of AFP, 
making AFP an apparently reliable choice. Regular checks 
of serum AFP levels in patients who originally had high AFP 
levels to recognize HCC recurrence is suggested as a practice 
guideline by the National Comprehensive Cancer Network 
(NCCN) version 1, 2009. Hepat Mon. 2011;11(3):155-156
156 Hepatocellular Recurrence after Orthotopic Liver Trasplantation Hashemi M et al
The whole AFP can be alienated into three different sub-frac-
tions, AFP-L1, AFP-L2, and AFP-L3, based on its reactivity to LCA 
on affinity electrophoresis. AFP-L1 does not react with LCA. It 
is increased in chronic hepatitis and liver cirrhosis and com-
prises a bulk fraction of the total AFP in non-malignant liver 
diseases. AFP-L2 is mostly derived from yolk sac tumors and 
could also be detected in maternal serum during pregnancy. 
AFP-L3 is the LCA-bound fraction of AFP. It has been reported 
that malignant liver cells produce AFP-L3, still when HCC is 
at its near the beginning stages (11). AFP-L3 has been estab-
lished to be a marker for HCC with a high specificity of 95%. 
AFP-L3-secreting hepatocytes have an increased tendency for 
rapid growth, early attack, and intrahepatic metastasis, thus 
leading to a poorer prognosis in affected individuals (12, 13). 
AFP and AFP-L3 levels decline to normal levels with effective 
therapy, and then rising levels suggest disease progression 
or recurrence. Therefore combination of total AFP and AFP-
L3 could be a very reliable biomarker for HCC and HCC recur-
rence in OLT. 
GPC-3 (also called DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB, 
SGBS,  and  SGBS1),  a  cell  exterior  protein,  is  extremely  ex-
pressed in HCC and some other human cancers including 
melanoma (14). The GPC3 gene encodes a   70-kDa-precursor 
core protein, which can be sliced by furin to make a 40-kDa 
amino (N) terminal protein and a 30-kDa membrane-bound 
carboxyl (C) terminal protein, which has two heparan sul-
phate (HS) glycan chains (15). The GPC3 protein is attached to 
the cell membrane by a glycosyl-phosphatidylinositol (GPI) 
anchor (16). GPC-3 is not expressed in hepatocytes of healthy 
subjects and patients with non-malignant hepatopathy, and 
can be detected in about 50% of HCC patients and 33% of HCC 
patients seronegative for AFP. The specificity of GPC-3 could 
be  considered  100%  according  to  some  previous  research 
(17). Some clinical studies have indicated that the simultane-
ous determination of GPC-3 and AFP could significantly in-
crease the sensitivity in HCC detection, without a reduction 
in the specificity (18). The clinical significance of changes in 
tumor markers after therapy has been investigated for vari-
ous solid tumors, and these changes are closely correlated 
with tumor response. For HCC, early studies have shown that 
AFP levels decrease rapidly after complete surgical resection 
and increase with tumor recurrence, suggesting that AFP 
response could potentially predict tumor response (19). A 
few recent studies highlighted the potential role of serial 
AFP screening in the evaluation of treatment response, with 
the supposition that AFP is indicative of tumor growth and 
activity (20, 21). Regarding the new research combination of 
total AFP, AFP-L3, and GPC-3 could be a good marker for HCC 
recurrence after OLT. Therefore Wang et al paper in this vol-
ume pointed out a very good beginning to monitor HCC pa-
tients who have under-gone the OLT and needs monitoring 
for tumor recurrence. 
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